- Home
- IMMP vs CVRX Comparison
IMMP vs CVRX Comparison
Compare IMMP & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- CVRX
- Stock Information
- Founded
- IMMP 1987
- CVRX 2000
- Country
- IMMP Australia
- CVRX United States
- Employees
- IMMP N/A
- CVRX N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IMMP Health Care
- CVRX Health Care
- Exchange
- IMMP Nasdaq
- CVRX Nasdaq
- Market Cap
- IMMP 211.1M
- CVRX 202.8M
- IPO Year
- IMMP N/A
- CVRX 2021
- Fundamental
- Price
- IMMP $1.89
- CVRX $5.44
- Analyst Decision
- IMMP Buy
- CVRX Buy
- Analyst Count
- IMMP 2
- CVRX 7
- Target Price
- IMMP $8.50
- CVRX $14.50
- AVG Volume (30 Days)
- IMMP 659.8K
- CVRX 444.5K
- Earning Date
- IMMP 05-23-2025
- CVRX 05-08-2025
- Dividend Yield
- IMMP N/A
- CVRX N/A
- EPS Growth
- IMMP N/A
- CVRX N/A
- EPS
- IMMP N/A
- CVRX N/A
- Revenue
- IMMP $3,019,249.00
- CVRX $52,870,000.00
- Revenue This Year
- IMMP $50.37
- CVRX $22.17
- Revenue Next Year
- IMMP N/A
- CVRX $24.02
- P/E Ratio
- IMMP N/A
- CVRX N/A
- Revenue Growth
- IMMP 24.11
- CVRX 25.62
- 52 Week Low
- IMMP $1.32
- CVRX $5.81
- 52 Week High
- IMMP $3.34
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- IMMP 54.39
- CVRX 34.75
- Support Level
- IMMP $1.78
- CVRX $4.30
- Resistance Level
- IMMP $2.71
- CVRX $7.91
- Average True Range (ATR)
- IMMP 0.17
- CVRX 0.61
- MACD
- IMMP 0.02
- CVRX -0.03
- Stochastic Oscillator
- IMMP 25.45
- CVRX 28.66
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.